These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 20079628)

  • 21. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
    Campone M; Rademaker-Lakhai JM; Bennouna J; Howell SB; Nowotnik DP; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):523-33. PubMed ID: 17308894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
    Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
    Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I clinical and pharmacokinetic study of oral penclomedine (NSC 338720) in adults with advanced solid malignancy.
    Liu G; Berlin J; Tutsch KD; Van Ummersen L; Dresen A; Marnocha R; Arzomanian R; Alberti D; Feierabend C; Binger K; Wilding G
    Clin Cancer Res; 2002 Mar; 8(3):706-11. PubMed ID: 11895899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
    Crul M; Rosing H; de Klerk GJ; Dubbelman R; Traiser M; Reichert S; Knebel NG; Schellens JH; Beijnen JH; ten Bokkel Huinink WW
    Eur J Cancer; 2002 Aug; 38(12):1615-21. PubMed ID: 12142051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors.
    Rubin EH; Rothermel J; Tesfaye F; Chen T; Hubert M; Ho YY; Hsu CH; Oza AM
    J Clin Oncol; 2005 Dec; 23(36):9120-9. PubMed ID: 16301595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer.
    Pourgholami MH; Szwajcer M; Chin M; Liauw W; Seef J; Galettis P; Morris DL; Links M
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):597-605. PubMed ID: 19904538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study.
    Ravaud A; Cerny T; Terret C; Wanders J; Bui BN; Hess D; Droz JP; Fumoleau P; Twelves C
    Eur J Cancer; 2005 Mar; 41(5):702-7. PubMed ID: 15763645
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors.
    de Jonge MJ; van der Gaast A; Planting AS; van Doorn L; Lems A; Boot I; Wanders J; Satomi M; Verweij J
    Clin Cancer Res; 2005 May; 11(10):3806-13. PubMed ID: 15897580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I and pharmacological study of weekly administration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. European Organization for Research and Treatment of Cancer Early Clinical Studies Group.
    Eskens FA; Greim GA; van Zuylen C; Wolff I; Denis LJ; Planting AS; Muskiet FA; Wanders J; Barbet NC; Choi L; Capdeville R; Verweij J; Hanauske AR; Bruntsch U
    Clin Cancer Res; 2000 May; 6(5):1736-43. PubMed ID: 10815892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.
    Figg WD; Monga M; Headlee D; Shah A; Chau CH; Peer C; Messman R; Elsayed YA; Murgo AJ; Melillo G; Ryan QC; Kalnitskiy M; Senderowicz AM; Hollingshead M; Arbuck SG; Sausville EA
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):955-67. PubMed ID: 25183650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I and pharmacokinetic study of anhydrovinblastine every 3 weeks in patients with refractory solid tumors.
    Ramnath N; Schwartz GN; Smith P; Bong D; Kanter P; Berdzik J; Creaven PJ
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):227-30. PubMed ID: 12655441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effects of food on the pharmacokinetic profile of oral vinorelbine.
    Bugat R; Variol P; Roché H; Fumoleau P; Robinet G; Senac I
    Cancer Chemother Pharmacol; 2002 Oct; 50(4):285-90. PubMed ID: 12357302
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
    Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
    Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I and pharmacokinetic study of SAM486A, a novel polyamine biosynthesis inhibitor, administered on a daily-times-five every-three-week schedule in patients with Advanced solid malignancies.
    Siu LL; Rowinsky EK; Hammond LA; Weiss GR; Hidalgo M; Clark GM; Moczygemba J; Choi L; Linnartz R; Barbet NC; Sklenar IT; Capdeville R; Gan G; Porter CW; Von Hoff DD; Eckhardt SG
    Clin Cancer Res; 2002 Jul; 8(7):2157-66. PubMed ID: 12114416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors.
    Hong DS; Abbruzzese JL; Bogaard K; Lassere Y; Fukushima M; Mita A; Kuwata K; Hoff PM
    Cancer; 2006 Sep; 107(6):1383-90. PubMed ID: 16902987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer.
    Van Ummersen L; Binger K; Volkman J; Marnocha R; Tutsch K; Kolesar J; Arzoomanian R; Alberti D; Wilding G
    Clin Cancer Res; 2004 Nov; 10(22):7450-6. PubMed ID: 15569974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome.
    Gojo I; Perl A; Luger S; Baer MR; Norsworthy KJ; Bauer KS; Tidwell M; Fleckinger S; Carroll M; Sausville EA
    Invest New Drugs; 2013 Oct; 31(5):1217-27. PubMed ID: 23443507
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perifosine in renal cell carcinoma.
    Srivastava N; Cho DC
    Expert Opin Investig Drugs; 2013 Feb; 22(2):285-91. PubMed ID: 23253151
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perifosine--a new option in treatment of acute myeloid leukemia?
    Krawczyk J; Keane N; Swords R; O'Dwyer M; Freeman CL; Giles FJ
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1315-27. PubMed ID: 23931614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.